UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 30, 2015
Shire plc
_________________________________________________________________________
(Exact name of registrant as specified in its charter)
Jersey, Channel Islands
_________________________________________________________________________
(State or other jurisdiction of incorporation)
0-29630 | 98-0601486 |
(Commission File Number) | (IRS Employer Identification No.) |
5 Riverwalk, Citywest Business Campus, Dublin
24, Republic of Ireland
_________________________________________________________________________
(Address of principal executive offices) | (Zip code) |
Registrant's telephone number, including area code | +353 1 429 7700 |
_________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))
Item 8.01. Other Events
Shire plc have issued the press releases attached hereto as Exhibit 99.1 and Exhibit 99.2 which are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibits are filed herewith:
99.1 | Press Release dated June 30, 2015 |
99.2 | Press Release dated July 1, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SHIRE PLC | ||
By: | /s/ M Enyedy | |
Name: | Mark Enyedy | |
Title: | Company Secretary |
Dated: July 1, 2015
EXHIBIT INDEX | |
Number |
Description
|
99.1 | Press Release dated June 30, 2015 |
99.2 | Press Release dated July 1, 2015 |
Exhibit 99.1
Press Release | ![]() |
www.shire.com |
Director/PDMR Share Dealings
June 30, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) of the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from April 1 to June 30, 2015.
Type of Security (1) | Number of Shares/ADSs | ||
Dominic Blakemore | Shares | 114 | |
William Burns | Shares | 126 | |
Dr. Steven Gillis | ADSs | 40 | |
Dr. David Ginsburg | ADSs | 36 | |
David Kappler | Shares | 126 | |
Susan Kilsby | ADSs | 133 | |
Anne Minto | Shares | 128 |
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £51.05 per Share and $241.4578 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations | ||
Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Exhibit 99.2
Press Release | ![]() |
www.shire.com |
Total Voting Rights
July 1, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following:
As at June 30, 2015, the Company’s issued ordinary share capital comprised 591,887,510 ordinary shares of 5 pence each with voting rights and a further 8,570,078 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 591,887,510. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations | ||
Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX